Alexandra Reiher, MD
Endocrinology, Diabetes & Metabolism · Lakewood, CONPI 1700046018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations.
Across 63 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$144
- Lilly USA, LLC$127
- Tandem Diabetes Care, Inc.$125
- Insulet Corporation$101
- BETA Bionics, Inc.$96
- Sanofi-aventis U.S. LLC$89
- plus $520 from 18 others
What the payments were for
- Food & beverage$1,201100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 5 | $144 |
| Lilly USA, LLC | 8 | $127 |
| Tandem Diabetes Care, Inc. | 7 | $125 |
| Insulet Corporation | 7 | $101 |
| BETA Bionics, Inc. | 4 | $96 |
| Sanofi-aventis U.S. LLC | 4 | $89 |
| AstraZeneca(2 entities) | 3 | $60 |
| Dexcom, Inc. | 3 | $56 |
| Antares Pharma, Inc. | 2 | $43 |
| Cequr Corporation | 2 | $40 |
| Abbott | 2 | $38 |
| Novo Nordisk | 2 | $37 |
| Sequel Med Tech, LLC | 2 | $34 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Johnson & Johnson | 1 | $26 |
| BD | 1 | $21 |
| Lifescan, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Mannkind Corporation | 1 | $17 |
| AbbVie | 1 | $16 |
| Radius Health, Inc. | 1 | $14 |
How this compares
$1,201 in reported general payments places this provider in the 55th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 146 | $184,853 |
| JardianceEmpagliflozin | 81 | $121,235 |
| TrulicityDulaglutide | 68 | $107,090 |
| OzempicSemaglutide | 70 | $85,837 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $77,522 |
| TymlosAbaloparatide | 22 | $57,016 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $37,026 |
| FarxigaDapagliflozin Propanediol | 33 | $35,337 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $17,195 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $16,431 |
| Humalog Kwikpen U-100Insulin Lispro | 43 | $14,048 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $12,134 |
| Novolog FlexpenInsulin Aspart | 39 | $10,713 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $9,011 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 57 | $8,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $127 | $302,416257 claims |
| Novo NordiskOzempic, Novolog | $37 | $90,35381 claims |
| Radius Health, Inc.Tymlos | $14 | $57,01622 claims |
| AstraZenecaFarxiga | $60 | $35,33733 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $30 | $8,072389 claims |
| AbbVieSynthroid | $16 | $5,65067 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Lakewood
- Kevin TongLakewood$3K
- Jennifer BernardLakewood$1K
- Rachana ThapaLakewood$967
- Leigh PerreaultBoulder$1.7M
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Michelle CassaraArvada$141K
- Halis AkturkAurora$109K
- Irinel StanciuArvada$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.